Biotech Giant Gilead Sciences Goes on Sale
Gilead Sciences stock was selling for a mere 7 times estimated 2016 earnings when I snapped up 150 shares.

I’m pretty sure my reaction to big stock market swings is different from that of most other investors. When stocks are on a roll, as they were in 2013 and 2014, I get increasingly nervous. By the time most investors have reached a state of irrational exuberance, I’m practically paralyzed with fear. When the market slumps, as it did early this year, I become euphoric and immediately start dusting off my wish list of stocks that I want to own.
As a result, I’ve gone on a bit of a buying binge this year, snapping up shares of five companies for my Practical Investing portfolio. I already held two of them, Apple (symbol AAPL, $109) and American Capital (ACAS, $15), and added to my positions when I thought they had become too cheap. Since my recent purchases, Apple has gained 14% and American Capital has climbed 9%. (All share prices and returns are as of March 31.)
New additions to the portfolio this year are General Motors (GM, $31), Gilead Sciences (GILD, $92) and AV Homes (AVHI, $11). As I mentioned last month, I bought GM because I thought the stock, selling at 5.5 times projected 2016 earnings and paying a generous dividend, was too inexpensive to pass up. So far, so good. Including a dividend payment, I earned 11% on my GM purchase in a month.

Sign up for Kiplinger’s Free E-Newsletters
Profit and prosper with the best of expert advice on investing, taxes, retirement, personal finance and more - straight to your e-mail.
Profit and prosper with the best of expert advice - straight to your e-mail.
I bought the other two stocks for similar reasons: They’re good companies, and their stocks reside in the bargain basement. I’ll provide more details about AV Homes, the smallest firm in my portfolio, next month.
Gilead is not small. The world’s most valuable biotech company, with a market capitalization of $124 billion, Gilead has grown at a blistering clip in recent years. Revenues in 2015 soared 31% from the year before, and profits jumped a stunning 62%. The stock, however, was selling for a paltry 7 times estimated 2016 earnings when I snapped up 150 shares at $90.81 each.
Strangely, the remarkable success of Sovaldi and Harvoni, Gilead’s drugs for the treatment of hepatitis C, goes a long way toward explaining the stock’s absurdly low valuation. The hepatitis C virus—a blood-borne killer that can go undetected for years—is believed to affect as many as 5.2 million Americans. Harvoni, in particular, has a much higher success rate and fewer side effects than the drug cocktails that were used to treat hepatitis in the past.
Sovaldi and Harvoni are classic examples of what the drug industry calls blockbusters. They accounted for 60% of Gilead’s 2015 revenues of $32.6 billion. But the drugs have been so successful at curing hepatitis C that fewer patients are expected to need them. That, coupled with increased competition from other drugs, may suppress future sales and prices.
And speaking of drug prices, what Americans pay for meds has become a hot political issue. Lawmakers have criticized Gilead for the astronomical prices it charges for Harvoni and Sovaldi. That raises the specter of drug-price regulation, a serious threat for biotech companies.
Unfavorable ruling. Finally, a jury recently sided with Merck in a lawsuit that contended that Gilead infringed on two Merck patents related to a key ingredient in both hepatitis drugs. Gilead is appealing. But if the ruling stands, Gilead may need to pay royalties on past and future sales, which would likely cut into profits.
All of these factors are expected to stymie Gilead’s growth, at least temporarily. Analysts expect both sales and earnings to dip by 3% in 2016. But Gilead’s track record suggests that its days as one of the preeminent growth companies in health care are far from over. Gilead is developing other antiviral treatments and cancer drugs, and it has been a wise buyer of small firms that have promising products in development. Bottom line: At today’s valuation, Gilead is a risk worth taking.
Profit and prosper with the best of Kiplinger's advice on investing, taxes, retirement, personal finance and much more. Delivered daily. Enter your email in the box and click Sign Me Up.

-
Cord Cutting Could Help You Save Over $10,000 in 10 Years
How cutting the cord can save you money and how those savings can grow over time.
-
The '8-Year Rule of Social Security' — A Retirement Rule
The '8-Year Rule of Social Security' holds that it's best to be like Ike — Eisenhower, that is. The five-star General knew a thing or two about good timing.
-
Stock Market Today: Stocks Stable as Inflation, Tariff Fears Ebb
Constructive trade war talks and improving consumer expectations are a healthy combination for financial markets.
-
Stock Market Today: "Good Trump" Gives Dow 740-Point Boost
Friday's headwind was Tuesday's tailwind, as President Trump's social media posts continue to drag and drive financial markets.
-
A Case Study in Mismatched Fund Returns
Stock Market Why do a fund's returns sometimes differ from its underlying index? A longstanding legal principle holds the key.
-
Stock Market Today: Stocks Drop as Trump Takes Aim at EU, Apple
The commander in chief issued new tariff threats against the European Union and the iPhone maker.
-
Stock Market Today: Dow Gains 1,160 Points on U.S.-China Trade Deal
The two countries agreed to a 90-day truce that will give them time to work on more substantive trade negotiations.
-
Stock Market Today: S&P 500 Nabs Longest Win Streak Since 2004
The stock market's rebound from its mid-April tariff-induced lows has been nothing short of impressive.
-
Stock Market Today: Dow Drops 971 Points as Powell Pressure Ramps Up
President Trump is increasing his attacks against Jerome Powell, insisting the Fed chair cut interest rates.
-
Wall Street Is Worried About Apple Stock. Should You Be, Too?
Analysts expect Trump's sweeping tariffs to have an outsized impact on Apple stock. How concerned should investors be?